Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Sarcoma, Ewing 2Sarcoma, Clear Cell 2Myoepithelioma 2Liposarcoma, Myxoid 2Histiocytoma, Angiomatoid Fibrous 2Desmoplastic Small Round Cell Tumor 2Chondrosarcoma, Extraskeletal Myxoid 2Sarcoma 1Fibroma 1

Interventions

Irinotecan 8Temozolomide 7FANG vaccine 4Topotecan 3Cyclophosphamide 3seclidemstat 2eribulin 2abemaciclib 2Pemetrexed 2Gemcitabine 2trifluridine tipiracil drug combination 1talazoparib 1surufatinib 1robatumumab 1regorafenib 1racotumomab 1palbociclib 1ganitumab 1figitumumab 1entrectinib 1dinutuximab 1copanlisib 1cixutumumab 1bempegaldesleukin 1Vincristine 1TB-403 1PM 01183 1PM 00104 1Nivolumab 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Sarcoma, Ewing × seclidemstat × Clear all
NCT03600649 2023-11-21

Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Salarius Pharmaceuticals, LLC

Phase 1 Unknown
50 enrolled
Sarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibroma, Myoepithelioma, Sarcoma, Sarcoma, Ewing, Liposarcoma, Myxoid, Sarcoma, Clear Cell, Desmoplastic Small Round Cell Tumor

NCT05266196 2023-08-01

A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

Salarius Pharmaceuticals, LLC

Phase 1/2 Unknown
10 enrolled
Sarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Myoepithelioma, Sarcoma, Ewing, Liposarcoma, Myxoid, Sarcoma, Clear Cell, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡